Result of AGM

RNS Number : 4648G

Oxford Biomedica PLC

06 June 2013

 

Oxford BioMedica plc Annual General Meeting

Oxford, UK - 06 June 2013: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares; and

·      Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2013 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (4 June 2013) there were 1,416,149,005 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolutions
1	798,015,210	718,720	3,930,170	98,838	836,022	803,598,960	Passed
2	797,418,859	719,921	3,930,170	553,064	891,828	803,513,842	Passed
3	797,776,116	719,067	3,930,170	234,065	866,983	803,526,401	Passed
4	797,854,651	721,377	3,930,170	152,287	867,916	803,526,401	Passed
5	797,585,441	722,136	3,930,170	394,241	834,413	803,466,401	Passed
6	797,028,458	784,413	3,930,170	951,823	904,096	803,598,960	Passed
7	796,847,889	760,464	3,930,170	1,029,913	957,965	803,526,401	Passed
Special resolutions
8	796,765,637	761,352	3,930,170	1,050,445	958,797	803,466,401	Passed
9	796,884,579	786,797	3,930,170	1,095,721	816,575	803,513,842	Passed

A copy of the slides presented at the AGM will be available on the Company's website after the meeting.  No new material information will be revealed at the meeting. 

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

RAGSSDFSMFDSELM